Title: Evaluation of Clinical Usefulness of Antikeratin Antibody,Antiperinuclear Factor and Anti-Cyclic Citrullinated Peptide Antibody in Juvenile Rheumatoid Arthritis
Abstract:Objective To evaluate the usefulness of antikeratin antibody(AKA),antiperinuclear factor(APF)and anti-cyclic citrullinated peptide antibody(anti-CCP)in distinguishing juvenile rheumatoid arthritis(JRA...Objective To evaluate the usefulness of antikeratin antibody(AKA),antiperinuclear factor(APF)and anti-cyclic citrullinated peptide antibody(anti-CCP)in distinguishing juvenile rheumatoid arthritis(JRA).Methods Seventy-six children with JRA were compared with 54 children with non JRA diseases and 30 healthy children.They were admitted during the same period and blood samples were collected for the study.Results There were no significant demographic differences among 3 groups.Sensitivity of each individual antibody was 30%-50% and combination could not increase the sensitivity.Specificity of each antibody was 50%-80% and combination increased the specificity to 80%-85%.ROC curve was performed to each antibody and combination.The areas under the ROC curve were only slightly over 0.5 and not significant.In JRA group,compared with AKA-negative children,more AKA-positive children presented joint stiffness,pericardial effusion,osteoporosis and antibody-positive of mycoplasma pneumoniae;they had higher ASO,ESR and CRP in the same group,compared with APF-negative children,more APF-positive children presented joint stiffness,osteoporosis and antibody-positive of mycoplasma pneumoniae;they had higher ASO,ESR and CRP.There was no significant difference in clinical symptoms,signs and laboratory examinations between anti-CCP positive and negative patients.Conclusions AKA,APF and anti-CCP can not improve early diagnostic sensitivity to JRA patients.AKA and APF have clinical value to estimate disease activity,pathology injury and prognosis.Read More
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot